Intravitreal Dexamethasone Implant as an alternative to systemic steroids as prophylaxis for Uveitic Cataract Surgery: A randomised trial
Phase 4
Completed
- Conditions
- Health Condition 1: null- Patients with intermediate or posterior uveitis and cataract scheduled for cataract surgeryHealth Condition 2: H309- Unspecified chorioretinal inflammation
- Registration Number
- CTRI/2017/08/009444
- Lead Sponsor
- Allergan India Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 43
Inclusion Criteria
Patients >18 years with 1) controlled intermediate or posterior uveitis and 2)cataract will be randomized to receive either intravitreal dexamethasone implant or systemic steroids as prophylaxis against recurrent inflammation.
Exclusion Criteria
1) Ocular/Systemic contraindications to steroids
2) Complicated cataract surgery
3) Attrition
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in visual acuity intra and inter group comparison on <br/ ><br> <br/ ><br>Change in retinal thickness on OCT both intra and intergroup comparisonTimepoint: Every month for 6 months for all outcomes <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method CHANGES IN CENTRAL SUBFIELD THICKNESS ON OCT, IF ANYTimepoint: EVERY MONTH FOR 6 MONTHS AFTER INTERVENTIO